IPCA Laboratories Q2 Results 2024:IPCA Laboratories declared their Q2 results for 2024 on 14 Nov, 2024, reporting a significant increase in both revenue and profit. The company achieved a revenue of ₹2354.9 crore, marking a 15.78% year-over-year growth. Notably, the profit surged to ₹229.48 crore, reflecting an impressive 58.2% increase compared to the same quarter last year.
In comparison to the previous quarter, IPCA Laboratories demonstrated strong growth, with revenue climbing by 12.53% and profit up by 19.37%. This consistent upward trend highlights the company’s robust operational performance during the quarter.
The selling, general, and administrative expenses saw an increase, rising by 4.5% quarter-over-quarter and 19.72% year-over-year. Despite the increase in expenses, the company managed to boost its operating income, which was up by 16.1% from the previous quarter and 47.72% year-over-year.
Earnings per share (EPS) for Q2 stood at ₹9.05, showcasing a remarkable increase of 58.22% year-over-year. This positive trend in earnings is likely to attract investor interest.
Despite a slight decline of -1.4% in the last week, IPCA Laboratories has delivered a 19.34% return over the past six months and an impressive 38.04% year-to-date return. The company’s market capitalization currently stands at ₹38,982.92 crore, with a 52-week high of ₹1708.65 and a low of ₹1041.
As of 15 Nov, 2024, the consensus among 12 analysts covering the company indicates a favorable outlook, with 3 analysts recommending ‘Sell’, 2 ‘Hold’, 4 ‘Buy’, and 3 ‘Strong Buy’. The general consensus recommendation remains to ‘Buy’, reflecting confidence in IPCA Laboratories’ growth potential.
IPCA Laboratories Financials
| Period | Q2 | Q1 | Q-o-Q Growth | Q2 | Y-o-Y Growth |
|---|---|---|---|---|---|
| Total Revenue | 2354.9 | 2092.63 | +12.53% | 2033.96 | +15.78% |
| Selling/ General/ Admin Expenses Total | 509.84 | 487.87 | +4.5% | 425.87 | +19.72% |
| Depreciation/ Amortization | 100.35 | 98.89 | +1.48% | 90.34 | +11.08% |
| Total Operating Expense | 2013.77 | 1798.8 | +11.95% | 1803.03 | +11.69% |
| Operating Income | 341.13 | 293.83 | +16.1% | 230.93 | +47.72% |
| Net Income Before Taxes | 344.83 | 290.39 | +18.75% | 225.36 | +53.01% |
| Net Income | 229.48 | 192.24 | +19.37% | 145.06 | +58.2% |
| Diluted Normalized EPS | 9.05 | 7.58 | +19.39% | 5.72 | +58.22% |
Disclaimer: This is an AI-generated live blog and has not been edited by LiveMint staff.
